Depienne Christel, Bouteiller Delphine, Keren Boris, Cheuret Emmanuel, Poirier Karine, Trouillard Oriane, Benyahia Baya, Quelin Chloé, Carpentier Wassila, Julia Sophie, Afenjar Alexandra, Gautier Agnès, Rivier François, Meyer Sophie, Berquin Patrick, Hélias Marie, Py Isabelle, Rivera Serge, Bahi-Buisson Nadia, Gourfinkel-An Isabelle, Cazeneuve Cécile, Ruberg Merle, Brice Alexis, Nabbout Rima, Leguern Eric
Département de Génétique et Cytogénétique, AP-HP, Fédération de Génétique, Hôpital de la Salpêtrière, Paris, France.
PLoS Genet. 2009 Feb;5(2):e1000381. doi: 10.1371/journal.pgen.1000381. Epub 2009 Feb 13.
Dravet syndrome (DS) is a genetically determined epileptic encephalopathy mainly caused by de novo mutations in the SCN1A gene. Since 2003, we have performed molecular analyses in a large series of patients with DS, 27% of whom were negative for mutations or rearrangements in SCN1A. In order to identify new genes responsible for the disorder in the SCN1A-negative patients, 41 probands were screened for micro-rearrangements with Illumina high-density SNP microarrays. A hemizygous deletion on chromosome Xq22.1, encompassing the PCDH19 gene, was found in one male patient. To confirm that PCDH19 is responsible for a Dravet-like syndrome, we sequenced its coding region in 73 additional SCN1A-negative patients. Nine different point mutations (four missense and five truncating mutations) were identified in 11 unrelated female patients. In addition, we demonstrated that the fibroblasts of our male patient were mosaic for the PCDH19 deletion. Patients with PCDH19 and SCN1A mutations had very similar clinical features including the association of early febrile and afebrile seizures, seizures occurring in clusters, developmental and language delays, behavioural disturbances, and cognitive regression. There were, however, slight but constant differences in the evolution of the patients, including fewer polymorphic seizures (in particular rare myoclonic jerks and atypical absences) in those with PCDH19 mutations. These results suggest that PCDH19 plays a major role in epileptic encephalopathies, with a clinical spectrum overlapping that of DS. This disorder mainly affects females. The identification of an affected mosaic male strongly supports the hypothesis that cellular interference is the pathogenic mechanism.
德拉韦特综合征(DS)是一种由基因决定的癫痫性脑病,主要由SCN1A基因的新发突变引起。自2003年以来,我们对大量DS患者进行了分子分析,其中27%的患者SCN1A基因的突变或重排呈阴性。为了确定SCN1A基因阴性患者中导致该疾病的新基因,我们使用Illumina高密度SNP微阵列对41名先证者进行了微重排筛查。在一名男性患者中发现了Xq22.1染色体上的半合子缺失,该缺失区域包含PCDH19基因。为了证实PCDH19基因与类似德拉韦特综合征有关,我们对另外73名SCN1A基因阴性患者的PCDH19基因编码区进行了测序。在11名无亲缘关系的女性患者中鉴定出9种不同的点突变(4种错义突变和5种截短突变)。此外,我们还证明了我们这位男性患者的成纤维细胞存在PCDH19基因缺失的嵌合体。PCDH19基因和SCN1A基因发生突变的患者具有非常相似的临床特征,包括早期热性和无热惊厥、成簇发作、发育和语言迟缓、行为障碍以及认知衰退。然而,患者的病情发展存在轻微但持续的差异,包括PCDH19基因突变的患者多形性惊厥较少(尤其是罕见的肌阵挛性抽搐和非典型失神发作)。这些结果表明,PCDH19基因在癫痫性脑病中起主要作用,其临床谱与DS重叠。这种疾病主要影响女性。一名受影响的嵌合男性患者的发现有力地支持了细胞干扰是致病机制这一假说。